R&D News | pharmaphorum

News

AbbVie climbs post-Allergan M&A peak with Apogee buy

AbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its 'mega-blockbuster' immunology pipeline.

News

Boehringer advances duo for aggressive cancers into phase 3

Boehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers.

News

Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance

Insilico Medicine has teamed up with SK Biopharmaceuticals on a wide-ranging, $2.5bn partnership to use AI to find neuroimmune drug candidates.

News

Sanofi names ex-Roche exec Fontoura as R&D chief

Paulo Fontoura, currently chief medical officer of Xaira Therapeutics, will replace Houmab Ashrafian as Sanofi's R&D head on 1st September.

News

Which biotechs have raised new VC financing this week?

Our latest roundup of financings in the biotech sector includes solid eight-figure rounds for Triveni, Cellares, HMNC, Vedana, and Neion Bio.

News

Heart drug biotech Kardigan raises $400m in upscaled IPO

Cardiovascular drug developer Kardigan has completed its IPO, raising substantially more than it originally anticipated.

AbbVie climbs post-Allergan M&A peak with Apogee buy

Boehringer advances duo for aggressive cancers into phase 3

Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance

Sanofi names ex-Roche exec Fontoura as R&D chief

Which biotechs have raised new VC financing this week?

Heart drug biotech Kardigan raises $400m in upscaled IPO

ASCO 2026: All about DNA damage response, with Luke Piggot

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks